A population-based cohort to study outcomes in end-stage liver disease patients
A population-based cohort to study outcomes in end-stage liver disease patients
批准号:
8633209
负责人:
David Seth Goldberg
金额:
$15.51万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-14 至 2018-07-31
关键词:
Advisory CommitteesAgeAlgorithmsAreaBiometryCaringCase MixesCessation of lifeClinicalCohort StudiesComorbidityComplexDataData AnalysesData SetData SourcesDatabasesDeteriorationDiseaseDisease OutcomeEducational process of instructingEnvironmentEpidemiologyEvaluationFosteringFutureGenderGeographic FactorGoalsHealth ServicesHepatologyHospitalizationImProvImprove AccessInterventionKnowledgeLeadLinkLiverLiver diseasesMedicaidMentorshipMethodsOrganOrgan TransplantationOutcomeOutcome StudyOutcomes ResearchPatientsPatternPennsylvaniaPhysiciansPoliciesPopulationPopulation DecreasesPublic HealthRegistriesResearchResearch PersonnelResourcesScientistSeveritiesSpecialistStagingStructureSystemTestingTransplantationUnited Network for Organ SharingUniversitiesVariantWorkadministrative databaseadverse outcomecareercohortdata sharingdensitygeographic differenceimprovedliver transplantationlow socioeconomic statusmalemedical schoolsmedical specialtiesmortalityneglectnovelpatient populationpopulation basedpreventpublic health relevance
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Although liver transplantation is lifesaving for patients with end-stage liver disease (ESLD), the scarcity of
cadaveric livers constrains its public health impact. Each year, approximately 6,000 patients undergo liver
transplantation in the U.S., while roughly 2,000 are removed from the waitlist due to death or clinical
deterioration.25 These 2,000 patients are a small fraction of the estimated 30,000 people that die each year
from complications of ESLD26, suggesting the scarcity of livers may cause a potentially large number of ESLD
patients to never be waitlisted. Indeed, the few available studies have estimated that less than 5% of potential
transplant candidates are ever waitlisted.27,28 There are very limited data on factors that influence who among
the population of patients with ESLD is listed for transplantation, and almost none of the data are population-
based. Some factors, such as gender and cause of ESLD can be studied in local settings. However, the
absence of nationally representative population-based data has prevented an in-depth evaluation of how
systemic factors, such as geographic variations in supply and demand influence listing practices for ESLD
patients. Thus, a population-based approach to studying ESLD is needed to bridge these unmet knowledge
gaps. This proposal aims to establish such a population-based dataset of ESLD, and to use this new resource
to test the central hypothesis that traditional research, focusing only on patients listed for liver transplantation,
fails to capture the true impact of listing practices and allocation policies. The work could shift the paradigm by
which future ESLD and transplant outcomes research is conducted to encompass population-level impacts of
policies and practices. This work will: a) employ two novel algorithms to generate a national cohort of ESLD
patients to be used for present and future ESLD outcomes research1,10~ b) identify potentially modifiable factors
(e.g. listing practices) that can improve access to transplantation and outcomes among all potential transplant
candidates~ and c) teach the applicant to use several new epidemiologic and demographic methods to foster
his goal of become a leading physician-scientist focused on improving outcomes for ESLD patients. The
specific aims are to: 1) identify patient and geographic factors associated with listing for transplantation among
ESLD patients~ 2) evaluate the total impact of local mismatches between liver supply and demand~ and 3)
examine how rates of listing for liver transplantation influence adverse patient outcomes among both waitlisted
patients and all local ESLD patients. The research structure at the University of Pennsylvania and the Clinical
Center for Epidemiology and Biostatistics, supplemented by the didactic coursework offered through the
Perelman School of Medicine at the University of Pennsylvania offer the optimal environment within which the
candidate will complete this work and foster his career as a clinician and independent investigator. Dr.
Goldberg has assembled a mentorship team with expertise in epidemiologic, health services, and hepatology
research, and an Advisory Committee with a longstanding track record of research and mentorship.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
3/4-The INTEGRATE Study: Evaluating INTEGRATEd Care to Improve Biopsychosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease
-
批准号:10710924
-
项目类别:
-
资助金额:$38.64万
-
财政年份:2023
-
负责人:David Seth Goldberg
-
依托单位:
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)
-
批准号:10605313
-
项目类别:
-
资助金额:$161.34万
-
财政年份:2021
-
负责人:David Seth Goldberg
-
依托单位:
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis
-
批准号:10491885
-
项目类别:
-
资助金额:$42.54万
-
财政年份:2021
-
负责人:David Seth Goldberg
-
依托单位:
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis
-
批准号:10700141
-
项目类别:
-
资助金额:$48.03万
-
财政年份:2021
-
负责人:David Seth Goldberg
-
依托单位:
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis
-
批准号:10310739
-
项目类别:
-
资助金额:$31.12万
-
财政年份:2021
-
负责人:David Seth Goldberg
-
依托单位:
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)
-
批准号:10095988
-
项目类别:
-
资助金额:$167.61万
-
财政年份:2021
-
负责人:David Seth Goldberg
-
依托单位:
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)
-
批准号:10392517
-
项目类别:
-
资助金额:$149.33万
-
财政年份:2021
-
负责人:David Seth Goldberg
-
依托单位:
Developing High-Quality Tools to Characterize Allograft Quality, Predict Transplant Outcomes and Expand Access to Kidney and Liver Transplantation
-
批准号:10201592
-
项目类别:
-
资助金额:$47.9万
-
财政年份:2020
-
负责人:David Seth Goldberg
-
依托单位:
Developing High-Quality Tools to Characterize Allograft Quality, Predict Transplant Outcomes and Expand Access to Kidney and Liver Transplantation
-
批准号:10605254
-
项目类别:
-
资助金额:$50.64万
-
财政年份:2020
-
负责人:David Seth Goldberg
-
依托单位:
Developing High-Quality Tools to Characterize Allograft Quality, Predict Transplant Outcomes and Expand Access to Kidney and Liver Transplantation
-
批准号:10413907
-
项目类别:
-
资助金额:$54.62万
-
财政年份:2020
-
负责人:David Seth Goldberg
-
依托单位:
Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation
-
批准号:10356830
-
项目类别:
-
资助金额:$51.28万
-
财政年份:2019
-
负责人:David Seth Goldberg
-
依托单位:
Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation
-
批准号:9891060
-
项目类别:
-
资助金额:$53.99万
-
财政年份:2019
-
负责人:David Seth Goldberg
-
依托单位:
Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation
-
批准号:10598508
-
项目类别:
-
资助金额:$47.68万
-
财政年份:2019
-
负责人:David Seth Goldberg
-
依托单位:
Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation
-
批准号:10083351
-
项目类别:
-
资助金额:$55.53万
-
财政年份:2019
-
负责人:David Seth Goldberg
-
依托单位:
A population-based cohort to study outcomes in end-stage liver disease patients
-
批准号:8733677
-
项目类别:
-
资助金额:$15.48万
-
财政年份:2013
-
负责人:David Seth Goldberg
-
依托单位:
A population-based cohort to study outcomes in end-stage liver disease patients
-
批准号:9324207
-
项目类别:
-
资助金额:$16.79万
-
财政年份:2013
-
负责人:David Seth Goldberg
-
依托单位:
A population-based cohort to study outcomes in end-stage liver disease patients
-
批准号:8899526
-
项目类别:
-
资助金额:$15.45万
-
财政年份:2013
-
负责人:David Seth Goldberg
-
依托单位:
Access to Liver Transplantation for Patients with Primary Sclerosing Cholangitis
-
批准号:8267243
-
项目类别:
-
资助金额:$5.02万
-
财政年份:2010
-
负责人:David Seth Goldberg
-
依托单位:
Access to Liver Transplantation for Patients with Primary Sclerosing Cholangitis
-
批准号:8000091
-
项目类别:
-
资助金额:$7.18万
-
财政年份:2010
-
负责人:David Seth Goldberg
-
依托单位:
ConProject-001
-
批准号:10083370
-
项目类别:
-
资助金额:$6.96万
-
财政年份:--
-
负责人:David Seth Goldberg
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: